Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapirolizumab Pegol in Moderate to Severe SLE
NCT02804763Phase 2Completed
- Sponsor
- UCB
- Start
- Jun 2016
- Primary completion
- May 2018
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 13
01
Overview
A Phase 2 trial of dapirolizumab pegol in systemic lupus erythematosus (SLE), sponsored by UCB. Started Jun 2016; status: completed.
02
Drugs
dapirolizumab pegol
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02804763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02804763.